Company profile: NeuroNexus
1.1 - Company Overview
Company description
- Provider of neural interface technology, components, and systems for neuroscience and clinical applications, including high-density SiNAPS CMOS probes; X-Series modular connector packages; X-Headstage implantable devices for recording and stimulation; XDAQ Core and XDAQ One electrophysiology data acquisition systems with IO Expander; and Z-Coat site coating to enhance probe performance in brain tissue.
Products and services
- XDAQ Core and XDAQ One: Flexible electrophysiology systems for data acquisition that capture single-unit, multi-unit, and local field potentials, part of the X-Series, with optional GPIO expansion via IO Expander
- SiNAPS: CMOS-integrated high-density neural probes for neural interface applications that record single-unit, multi-unit, and local field potentials for electrophysiology in neuroscience and clinical contexts
- X-Headstage: Implantable recording and stimulation devices within the X-Series that capture neural signals and deliver stimulation for neuroscience and clinical applications in electrophysiology workflows
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NeuroNexus
CNS Therapeutics
HQ: United States
Website
- Description: Provider of pharmaceuticals for site-specific delivery to the central nervous system to treat neurological disorders and chronic pain; develops and markets safe, high-quality pharmaceuticals, including its first FDA-approved product, Gablofen. Based in St. Paul, Minn.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CNS Therapeutics company profile →
Braeburn
HQ: United States
Website
- Description: Provider of opioid use disorder solutions, including BRIXADI, a weekly and monthly injectable medication for moderate to severe OUD, and an Investigator-Initiated Trials program that supports independent research to advance medical and scientific understanding of its products and related therapeutic areas.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Braeburn company profile →
Brain Scientific
HQ: United States
Website
- Description: Provider of high-tech, clinical-grade neurological diagnostic devices designed to extend the reach and capability of telemedicine in neurology (teleneurology).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Brain Scientific company profile →
Afferent Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for chronic pain, developing medicines that target P2X3 receptors in nerve fibers. Its lead compound, AF-219, has completed two Phase 1 clinical studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Afferent Pharmaceuticals company profile →
Adapt Pharma
HQ: United States
Website
- Description: Provider of therapeutic treatments for patients with special medical conditions, including NARCAN (naloxone hydrochloride) Nasal Spray, an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adapt Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NeuroNexus
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NeuroNexus
2.2 - Growth funds investing in similar companies to NeuroNexus
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NeuroNexus
4.2 - Public trading comparable groups for NeuroNexus
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →